
FDA Approves Genentech's Tecentriq for Stage III dMMR Colon Cancer.
PLUS: MRI2CT's AI generates 3D bone CTs from routine spine MRIs.
The Daily Signal
The daily newsletter, published here the moment it lands in inboxes. Read the archive in full when you join the list.

PLUS: MRI2CT's AI generates 3D bone CTs from routine spine MRIs.

PLUS: How Novartis took oral BTK inhibition into physical friction hives.

PLUS: How Genmab and AbbVie's bispecific cut lymphoma progression by 51%.

PLUS: Vaxcyte’s 31-valent vaccine meets pivotal Phase 3 endpoints; Abbott wins approval to show CardioMEMS readings to patients.

PLUS: Jaypirca gets approved as an Initial Treatment for Certain Adults With CLL/SLL

PLUS: How pediatric myosin inhibition changes congenital cardiology forever.

PLUS: The Bedside Diagnostic Wave: Economics of Point-of-Care Neuromonitoring and Cyclical Thrombectomy

PLUS: The end of 60-minute endoscopic frame scrubbing & ER triage margins

PLUS: The MCT8 Treatment Boundary: What Emcitate’s Approval Changes and What It Leaves Open

PLUS: The HealthTech Signal Plus: Stentless Cath Lab Economics & Receptor Subtype Neurology

PLUS: Inside the Once-Weekly Metabolic Shift & Outpatient Cardiology Economics

PLUS: Why Early-Line Disease Modification Changes Healthcare Valuation Multiples

PLUS: Inside the MCED Diagnostic Cascade & Generic Radiopharmaceutical Economics

PLUS: FDA clears MICSI-PET AI and Ultragenyx wins landmark gene therapy approval

PLUS: The $10,000 cath lab false alarm calculus, oral SERD companion diagnostic moats, and crossover trial biology.

PLUS: Why sentence-level provenance is pharma's new RWE moat

PLUS: Altis Labs $25M for AI endpoints and Sling's $123M oral TED pill

PLUS: What the De Novo classification means for every hospital's liability exposure

PLUS: FDA launches Expedited IND Pilot, RegCell's $66M Nobel-backed round, and the end of PMA companion diagnostic barriers.

PLUS: Implicity's $40M cardiac round, Thyme Care $2B valuation, and why SaaS is pivoting to full-stack care.

PLUS: Scholar Rock's muscle breakthrough, Forus $3B valuation, and the new theranostic playbook.

PLUS: 🏥 Inspiren hits $500M valuation to eliminate unwitnessed falls

PLUS: Frazier adds $1.1B, Implicity raises $40M, and clinical AI gets continuous audits

PLUS: How AI ultrasound cut DVT diagnosis to 30 minutes at NHS Chelsea

PLUS: An AI-designed drug reversed aging markers. And Adventist Health unified 27 hospitals on one record.

PLUS: The Australian health AI that took $32M to stay home, then left.

Oracle rolls out its native clinical AI agent globally while iRhythm and Butterfly Network secure major regulatory wins to expand their hardware footprints.

PLUS: FDA approves the first drug for a disease so rare, half its patients haven't been found yet

PLUS: Ezekiel Emanuel says doctors will degrade AI outcomes by 2030

PLUS: The cardiac MRI AI that gets to update itself, and a federated clinical data network now at 9 medical centers.

PLUS: Stryker put the OR data in a headset, first surgery completed.

PLUS: Bayesian Health's sepsis AI found 46% more cases, here's what 'validated' actually looks like

PLUS: AI generates your full molecular portrait from routine bloods, and cuts invasive heart procedures by 44%.

PLUS: Sword Health is paying up to $300M for Headspace..

PLUS: Sword Health acquires Headspace for $200-300M, effective Sept 14.

PLUS: Tempus AI just got FDA clearance for a third cardiovascular tool

PLUS: Cleveland Clinic published the AI scribe deployment blueprint every health system has been waiting for.

PLUS: R1 buys Humata to automate prior auth.

Researchers ran 376 unsolved cases through OpenAI's o3 model. It surfaced answers in 18 of them. Cases doctors had been stuck on for years, some for over a decade.

The company's latest funding round highlights a growing trend: the most valuable AI businesses are fixing industries from the inside out.

For decades, prevention was a hard sell. Now healthy people are coming back before anything goes wrong.